Last reviewed · How we verify

brimonidine 0.1%

Augenarztpraxis Breisach · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

brimonidine 0.1% is a Small molecule drug developed by Augenarztpraxis Breisach. It is currently FDA-approved.

Brimonidine 0.1% is a small molecule used to treat conditions such as glaucoma, ocular hypertension, and normal tension glaucoma. It is used as an intervention in clinical trials to control intraocular pressure.

At a glance

Generic namebrimonidine 0.1%
SponsorAugenarztpraxis Breisach
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about brimonidine 0.1%

What is brimonidine 0.1%?

brimonidine 0.1% is a Small molecule drug developed by Augenarztpraxis Breisach.

Who makes brimonidine 0.1%?

brimonidine 0.1% is developed and marketed by Augenarztpraxis Breisach (see full Augenarztpraxis Breisach pipeline at /company/augenarztpraxis-breisach).

What development phase is brimonidine 0.1% in?

brimonidine 0.1% is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing